Rep. Steve Cohen Sells Off Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Emergent BioSolutions stock on December 11th. The trade occurred in the Representative’s “STEPHENS SEP IRA” account.

Representative Steve Cohen also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Host Hotels & Resorts (NASDAQ:HST) on 12/11/2024.

Emergent BioSolutions Trading Down 0.4 %

EBS stock opened at $9.37 on Wednesday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market capitalization of $507.70 million, a PE ratio of -2.29 and a beta of 1.60. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The company’s 50-day simple moving average is $9.36 and its 200 day simple moving average is $9.17.

Wall Street Analyst Weigh In

EBS has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Friday, January 10th. Benchmark upped their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Tuesday.

Institutional Investors Weigh In On Emergent BioSolutions

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. raised its position in Emergent BioSolutions by 1,314.0% in the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after purchasing an additional 253,960 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at about $1,547,000. Headlands Technologies LLC bought a new position in shares of Emergent BioSolutions during the second quarter worth about $969,000. Oak Hill Advisors LP bought a new position in shares of Emergent BioSolutions during the third quarter worth about $9,296,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after acquiring an additional 316,700 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

About Representative Cohen

Steve Cohen (Democratic Party) is a member of the U.S. House, representing Tennessee’s 9th Congressional District. He assumed office on January 3, 2007. His current term ends on January 3, 2025. Cohen (Democratic Party) is running for re-election to the U.S. House to represent Tennessee’s 9th Congressional District. He declared candidacy for the Democratic primary scheduled on August 1, 2024. He represented District 30 of the Tennessee State Senate from 1983-2006. As a child, Cohen contracted polio. Cohen filed to run for his first elected office the same day that he first registered to vote. Cohen earned a bachelor’s degree from Vanderbilt and a J.D. from the University of Memphis School of Law. Prior to his election to the U.S. House, Cohen was a member of the Tennessee State Senate.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.